SCHEMBL274700

SCHEMBL274700

COC(=O)c1cc(C)c(N)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.55
ALDH1A1 P00352 6/20 0.55
GAA P10253 5/20 0.55
MAPT P10636 4/20 0.55
HSD17B10 Q99714 3/20 0.55
HPGD P15428 3/20 0.55
GLA P06280 2/20 0.55
CASP1 P29466 1/20 0.55
CASP7 P55210 1/20 0.55
ATM Q13315 1/20 0.55
CFTR P13569 3/20 0.50
ABL1 P00519 1/20 0.49
TSHR P16473 3/20 0.47
ALOX15 P16050 1/20 0.47
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 1/20 0.44
POLB P06746 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
PDGFRB P09619 1/20 0.42
FGFR1 P11362 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5417457 0.98 KDM4E (0.53) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL30280995 0.92 KDM4E (0.55) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL2318882 0.92 KDM4E (0.55) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL2811951 0.90 KDM4E (0.53) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL1720999 0.90 KDM4E (0.56) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL2897750 0.88 KDM4E (0.61) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL2430255 0.87 KDM4E (0.50) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL17596509 0.87 KDM4E (0.50) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL681252 0.86 KDM4E (0.63) KDM4EALDH1A1GAAMAPTHSD17B10
SCHEMBL24821258 0.83 KDM4E (0.50) KDM4EALDH1A1GAAMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150339-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2024-05-09 US disclosed
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2024-01-25 US disclosed
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2024-01-25 US disclosed
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CORTEVA AGRISCIENCE LLC (US) 2024-01-25 US disclosed
WO-2023244818-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
EP-4291557-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2023-12-20 EP disclosed
CN-116848107-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2023-10-03 CN disclosed
EP-4247789-A1 FUNGICIDAL ARYL AMIDINES Corteva Agriscience LLC (US) 2023-09-27 EP disclosed
CN-116529235-A Fungicidal aryl amidines 科迪华农业科技有限责任公司 2023-08-01 CN disclosed
WO-2022172037-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2022-08-18 WO disclosed
US-20100137603-A1 DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY THERAVANCE, INC. (US) 2010-06-03 US disclosed
US-7687521-B2 Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity THERAVANCE, INC. (US) 2010-03-30 US disclosed
US-20090176833-A1 DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY THERAVANCE BIOPHARMA R&D IP, LLC 2009-07-09 US disclosed
US-7524965-B2 Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity THERAVANCE, INC. (US) 2009-04-28 US disclosed
EP-2010489-A2 DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY Theravance, Inc. (US) 2009-01-07 EP disclosed
EP-2010490-A2 CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND Theravance, Inc. (US) 2009-01-07 EP disclosed
WO-2007127297-A2 CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND THERAVANCE, INC. (US) 2007-11-08 WO disclosed
WO-2007127196-A2 DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY THERAVANCE, INC. (US) 2007-11-08 WO disclosed
US-20070249674-A1 Crystalline forms of a dimethylphenyl compound THERAVANCE BIOPHARMA R&D IP, LLC 2007-10-25 US disclosed
US-20070249675-A1 Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity THERAVANCE BIOPHARMA R&D IP, LLC 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249674-A1 Crystalline forms of a dimethylphenyl compound H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, PKD1 KDM4E 178/4885ALDH1A1 3505/4885GAA 1363/4885
US-20240023549-A1 FUNGICIDAL ARYL AMIDINES CYP1A1, CYP1A2, CYP1B1 KDM4E 648/4885ALDH1A1 105/4885GAA 512/4885
US-20100137603-A1 DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY ADRB2, ADRB1, ADRA2C KDM4E 3504/4885ALDH1A1 772/4885GAA 3421/4885
US-20090176833-A1 DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY ADRB2, ADRB1, ADRA2C KDM4E 3504/4885ALDH1A1 772/4885GAA 3421/4885
US-20070249675-A1 Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity ADRB2, ADRB1, ADRA2C KDM4E 3504/4885ALDH1A1 772/4885GAA 3421/4885
US-20240150339-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE4B, PDE4C KDM4E 1809/4885ALDH1A1 808/4885GAA 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.